Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc at Robert W Baird Global Healthcare Conference Transcript

Sep 13, 2022 / 04:50PM GMT
Release Date Price: €5.28
Colleen Kusy
Robert W. Baird & Co. Incorporated - Analyst

Good afternoon, everyone. Thanks for joining with us for the Baird Global Healthcare Conference. My name is Colleen Kusy. I'm one of the senior analyst covering biotech at Baird. I'm pleased to have with me Karyopharm Therapeutics. With us is Richard Paulson, CEO; and Dr. Reshma Rangwala, Chief Medical Officer. Thank you both for being here.

Richard Paulson
Karyopharm Therapeutics Inc. - CEO

Thank you for having us.

Reshma Rangwala
Karyopharm Therapeutics Inc. - Chief Medical Officer

Thank you.

Colleen Kusy
Robert W. Baird & Co. Incorporated - Analyst

So for those of you who are a little less familiar with Karyopharm, let's maybe start off just with a brief company overview.

Richard Paulson
Karyopharm Therapeutics Inc. - CEO

Sure. And thanks, Colleen. Thanks for having us. As a company overview, maybe I'll just go through a few slides. Karyopharm is an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot